Collin Ganser, Ph.D., is a Research Senior Scientist in the Pre-Clinical Development group at the ChristianaCare Gene Editing Institute. At the Gene Editing Institute, he is characterizing the efficacy of CRISPR-directed gene editing that disrupts the transcription factor NRF2 in lung squamous cell carcinoma to restore sensitivity to chemotherapy and to reduce tumor burden. Dr. Ganser received his Ph.D. in Pathobiology in 2025 from Brown University, where he studied epigenetic transitions in the human fungal pathogen Candida albicans. His prior research dissected genetic interactions and biomolecular condensation of transcription factors that regulate C. albicans’ epigenetic transitions.
